Meliane

Ethinylestradiol and Gestodene, the active ingredients in Meliane, are a combined oral contraceptive presented as a tablet for oral use. It prevents pregnancy by inhibiting ovulation and altering cervical mucus in women of reproductive age.

GNH USA supplies Meliane as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meliane, a combined oral contraceptive, is used within the hormonal contraception pathway to prevent pregnancy.

Contraception: prevention of unintended pregnancy in women of childbearing potential. Menstrual cycle regulation: reduction of menstrual bleeding and improvement of cycle regularity. Acne treatment: improvement of moderate acne associated with hormonal fluctuations. Dysmenorrhea relief: alleviation of painful menstrual cramps.

Common Side Effects: - Nausea: mild to moderate stomach upset, especially during the first cycles. - Breast tenderness: temporary swelling or discomfort of the breasts. - Headache: occasional tension‑type or migraine‑like headaches. - Spotting: irregular light bleeding between periods. - Mood changes: fluctuations in mood or mild depressive symptoms. - Weight gain: modest increase in body weight, often due to fluid retention.

Serious or Rare Side Effects: - Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism. - Arterial thrombosis: stroke or myocardial infarction. - Hypertension: new‑onset or worsening high blood pressure. - Liver tumor: benign hepatic adenoma. - Severe allergic reaction: anaphylaxis, angioedema, or skin rash. - Visual disturbances: sudden vision loss or blurred vision.

Before prescribing Meliane, clinicians should evaluate individual risk factors and contraindications.

Contraindications: known thrombophilia, estrogen‑dependent neoplasia, pregnancy, or lactation. Smoking: avoid use in women over 35 who smoke regularly. Cardiovascular risk: assess hypertension, diabetes, or hyperlipidaemia before initiation. Drug interactions: review concomitant medications that induce or inhibit CYP3A4 metabolism. Regular monitoring: periodic blood pressure and lipid profile checks are advisable. Store at ambient temperature: keep below 25°C, retain in the original packaging, and protect from moisture and light.

Meliane may interact with several medicines that alter hormone levels or clotting risk.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin): may markedly reduce contraceptive efficacy. - Anticoagulants (e.g., warfarin): hormonal components can affect coagulation parameters. - Certain antiretrovirals (e.g., efavirenz): may decrease plasma concentrations of the active ingredients.

Moderate Interactions (Monitor Closely): - Antifungals (e.g., ketoconazole, itraconazole): can increase hormone levels, raising side‑effect risk. - SSRIs (e.g., fluoxetine, sertraline): may enhance bleeding tendency. - Herbal supplements (e.g., St. John’s wort): may lower contraceptive effectiveness.